Skip to main content
Vitrolife logo

Vitrolife — Investor Relations & Filings

Ticker · VITR ISIN · SE0011205202 LEI · 5493001WDZMONMSPPR49 ST Manufacturing
Open in API
Filings indexed 656 across all filing types
Latest filing 2009-02-18 M&A Activity
Country SE Sweden
Listing ST VITR

About Vitrolife

https://www.vitrolife.com/

Vitrolife is a global company focused on reproductive health, providing medical devices and genetic testing services primarily to In Vitro Fertilization (IVF) clinics. The company develops, produces, and markets a comprehensive portfolio of products and solutions that support the entire assisted reproduction treatment journey, from oocyte retrieval and sperm preparation to fertilization, embryo culture, evaluation, transfer, and cryopreservation. With a strong emphasis on quality control, innovation, and clinical support, Vitrolife aims to improve treatment outcomes and operational efficiency for its partners. The company also offers educational resources and training for professionals through its Vitrolife Academy.

Recent filings

Filing Released Lang Actions
M&A Activity 2009
M&A Activity Classification · 99% confidence The document is a press release announcing an extension of the acceptance period for a voluntary share exchange offer (a takeover bid) concerning the acquisition of MediCult by Vitrolife. This activity falls directly under the definition of M&A Activity (merger or takeover proposals). The document is short and functions as an announcement, but the core subject matter is a takeover bid, which maps specifically to the 'M&A Activity' category (TAR), rather than the general 'Report Publication Announcement' (RPA) or 'Regulatory Filing' (RNS), as it details the terms of the transaction itself. Keywords: 'frivilliga aktiebyteserbjudandet' (voluntary share exchange offer), 'förvärva aktierna' (acquire the shares), 'erbjudandehandlingen' (offer document).
2009-02-18 Swedish
M&A Activity 2009
M&A Activity Classification · 99% confidence The document explicitly discusses the extension of a voluntary exchange offer (a takeover bid) by Vitrolife for MediCult shares. This action falls directly under the definition of M&A Activity, which corresponds to the Takeover/Merger Activity code (TAR). Keywords supporting this: 'voluntary exchange offer', 'offer period', 'purchase the shares in MediCult'. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is a specific announcement related to a corporate transaction involving acquisition/takeover.
2009-02-18 English
Regulatory Filings 2009
Regulatory Filings Classification · 95% confidence The document is a press release (indicated by "Pressmeddelande") announcing a specific regulatory achievement: the Swemed Sense™ product received 510(k) clearance from the US Food and Drug Administration (FDA). This is a factual announcement about a product approval and market expansion, not a comprehensive financial report (like 10-K or IR), a management change (MANG), or a dividend notice (DIV). Since it is a specific, non-financial regulatory/product update that doesn't fit the other specific categories (like DVA, CAP, DIRS, etc.), it falls best under the general Regulatory Filings category (RNS) or potentially a general announcement. Given the options, RNS is the most appropriate catch-all for significant, non-financial regulatory news that isn't a standard SEC filing type listed.
2009-02-16 Swedish
Regulatory Filings 2009
Regulatory Filings Classification · 95% confidence The document is explicitly titled as a "Press release" dated February 16, 2009, announcing a specific event: the FDA approval (510(k) clearance) for a new product, Swemed Sense™. This is a general corporate announcement regarding a regulatory milestone and product launch, not a comprehensive financial report (like 10-K or IR), a transcript (CT), or a specific shareholder/insider filing (like DIRS or DVA). Since it is a general announcement that doesn't fit the specific categories like ER (Earnings Release) or CAP (Financing Update), the most appropriate general category for non-standard, non-financial regulatory/corporate news is Regulatory Filings (RNS), which serves as a broad category for such press releases that convey important operational or regulatory news.
2009-02-16 English
Interim / Quarterly Report 2008
Interim / Quarterly Report Classification · 100% confidence The document is a 'Report on operations 2008' for Vitrolife AB, specifically detailing Q4 and full-year financial performance, including sales, gross income, operating income, and cash flow. It contains detailed financial statements and analysis for a period shorter than a full fiscal year (Q4) and the full year, fitting the definition of an Interim/Quarterly Report. It is not a mere announcement (RPA) as it contains substantive financial data and analysis. Q4 2008
2009-02-12 English
Earnings Release 2008
Earnings Release Classification · 99% confidence The document is titled "Bokslutskommuniké 2008" (Year-End Report Communication 2008) and contains detailed financial summaries for the full year and the fourth quarter (Q4), including revenue, gross margin, operating income, net income, cash flow, and segment performance (Fertility, Transplantation, Stem Cell Cultivation). The content is comprehensive, covering operational highlights, strategic moves (acquisitions, clinical trials), and full financial statements/metrics, which strongly indicates a full annual financial report or a detailed summary thereof. Since it is a 'Bokslutskommuniké' (Year-End Report Communication) and provides extensive financial detail, it aligns best with the comprehensive nature of an Annual Report (10-K) or a detailed Interim/Quarterly Report (IR). Given the title explicitly refers to the year-end results ('Bokslutskommuniké'), it represents the culmination of the annual reporting cycle. Although it is a communication, its length (nearly 50,000 characters) and depth suggest it is the primary annual financial disclosure, rather than just a brief announcement (RPA). In the context of the provided definitions, this detailed year-end financial summary is most appropriately classified as an Annual Report (10-K) equivalent, or if strictly adhering to the definitions, the most comprehensive financial report, which is 10-K for US filers, or AR if it were just the audit section. Since it contains the full results, 10-K is the closest fit for a comprehensive annual financial disclosure, even if the company is Swedish (using 'Bokslutskommuniké'). If 10-K is reserved strictly for SEC filings, then AR (Audit Report/Information) is the next best fit for a comprehensive annual financial document that isn't a quarterly report (IR). However, given the depth, it functions as the primary annual financial report. I will classify it as 10-K as it represents the full annual financial performance disclosure. Q4 2008
2009-02-12 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.